ID   E006AA
AC   CVCL_4834
SY   E006AA-Par; E006AA-Pr
DR   cancercelllines; CVCL_4834
DR   Millipore; SCC102
DR   Wikidata; Q38514722
RX   CelloPub=CLPUB00549;
RX   PubMed=15162380;
RX   PubMed=25076860;
RX   PubMed=31416301;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a 786-O derivative (PubMed=31416301). Originally thought to originate from a 50 year old patient with prostate carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00585.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; c.560-2A>G; ClinVar=VCV003148158; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line).
CC   Discontinued: Millipore; SCC102; true.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): Millipore=SCC102
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8
ST   D16S539: 12
ST   D18S51: 13,14
ST   D21S11: 29,30
ST   D3S1358: 16
ST   D5S818: 9
ST   D7S820: 11
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 9,12
ST   Penta E: 7,16
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 15,17
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1051 ! 786-O
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 23
CH   CVCL_YI81 ! E006AA ZIC2-/- E5
CH   CVCL_YI82 ! E006AA ZIC2-/- G12
CH   CVCL_X480 ! E006AA-hT
//
RX   PubMed=31416301; DOI=10.1002/pros.23800;
RA   Koochekpour, Shahriar
RA   Maresh, Grace A.
RA   Katner, Adrienne
RA   Parker-Johnson, KiTani
RA   Lee, Tae-Jin
RA   Hebert, Francine E.
RA   Kao, Yuan S.
RA   Skinner, John
RA   Rayford, Walter
RT   "Correction: Establishment and characterization of a primary
RT   androgen-responsive African-American prostate cancer cell line,
RT   E006AA. Prostate 2004;60(2):145-152.";
RL   Prostate 79:815-815(2019).
//
RX   PubMed=25076860; DOI=10.7150/ijbs.9406; PMCID=PMC4115195;
RA   Koochekpour, Shahriar
RA   Willard, Stacey S.
RA   Shourideh, Mojgan
RA   Ali, Shafat
RA   Liu, Chun-Hong
RA   Azabdaftari, Gissou
RA   Saleem, Mohammad
RA   Attwood, Kristopher M.
RT   "Establishment and characterization of a highly tumorigenic African
RT   American prostate cancer cell line, E006AA-hT.";
RL   Int. J. Biol. Sci. 10:834-845(2014).
//
RX   CelloPub=CLPUB00549;
RA   Moore, Jennifer C.
RT   "Establishment Of CRISPR/Cas-9 aided knockout of the ZIC2 gene in the
RT   African-American prostate cancer cell line E006AA-PR.";
RL   Thesis MSc (2019); Clark Atlanta University; Atlanta; USA.
//
RX   PubMed=15162380; DOI=10.1002/pros.20053;
RA   Koochekpour, Shahriar
RA   Maresh, Grace A.
RA   Katner, Adrienne
RA   Parker-Johnson, KiTani
RA   Lee, Tae-Jin
RA   Hebert, Francine E.
RA   Kao, Yuan S.
RA   Skinner, John
RA   Rayford, Walter
RT   "Establishment and characterization of a primary androgen-responsive
RT   African-American prostate cancer cell line, E006AA.";
RL   Prostate 60:141-152(2004).
//